mRNA-1189
Phase 2Active 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Epstein-Barr Virus Infection
Conditions
Epstein-Barr Virus Infection
Trial Timeline
Dec 28, 2021 → Oct 5, 2026
NCT ID
NCT05164094About mRNA-1189
mRNA-1189 is a phase 2 stage product being developed by Moderna for Epstein-Barr Virus Infection. The current trial status is active. This product is registered under clinical trial identifier NCT05164094. Target conditions include Epstein-Barr Virus Infection.
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07478952 | Phase 1 | Recruiting |
| NCT05164094 | Phase 2 | Active |
Competing Products
5 competing products in Epstein-Barr Virus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1189 | Moderna | Phase 1 | 0 |
| mRNA-1195.1 | Moderna | Phase 1 | 0 |
| Nanatinostat in combination with valganciclovir | Viracta Therapeutics | Phase 2 | 17 |
| Durvalumab + Epacadostat | AstraZeneca | Phase 2 | 27 |
| tabelecleucel | Atara Biotherapeutics | Pre-clinical | 16 |